NCT05661110Not yet recruiting
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis
Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1/PDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis
Source: ClinicalTrials.gov · Last updated 22 Dec 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with peritoneal metastasis. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 46 (estimated)
- First submitted
- 5 Dec 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05661110
What you commit to
- Study type: Observational
- Planned participants: 46
- From 1 Jan 2023 to the primary completion date, 31 Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);
- Other patients who were considered unsuitable for inclusion by the researchers;
Who the study is looking for
- Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;
- Age 18-75 years, Male or Non-pregnant female
- Eastern Cooperative Oncology Group(ECOG): 0\~1；
- Negative for human epidermal growth factor receptor 2(HER-2) by immunocytochemistry or fluorescence in situ hybridization；
- The presence of gastric cancer peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；
- Patients had received HIPEC combined with PD1/PDL1 inhibitor conversion therapy.
- Signed the Informed Consent Form, and blood and tissue samples can be obtained;
Age in the registry: 18 years to 75 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.